No abstract available.

The purpose of this study was to investigate the inhibitory role of vitamin A with respect to activation of Ito cells in fibrosis of the rat liver induced by common bile duct ligation(CBDL). The liver was examined by immunohistochemical staining for a-smooth muscle actin,the known marker of activated Ito cells, and light and electron microscopy after CBDL andCBDL with intraperitoneal injection of retinoic acid (Sigma, USA) 1 mg/Kg in 3 times per week. The results were sumrrlerized as follows: After CBDL, the bile ductules were markedly proliferated in the periportal areas extending toterminal hepatic veins. Interstitial fibrosis and inflammatory cell infiltration appeared, however,cholestasis was minimal. Retinoic acid treatment with CBDL decreased bile ductular proliferationand interstitial fibrosis compared to CBDL only. After CBDL, proliferated and activated Ito ceIs showing positive reaction in smooth muscle actin were present in the periductular andperisinusoidal areas, and areas of increased interstitial fibrosis. Activated ito cells weredecreased in number after CBDL with vitamin A treatment. Electron microscopically,intracytoplasmic fat droplets and the cytoplasmic processes of Ito cells were decreased afterCBDL. Myofibroblasts were frequently appeared in the interstitial fibrosis after CBDL. But,intracytoplasmic fat droplets of Ito cells were well preserved, and myofibroblasts were found lessfrequently after CBDL with vitamin A treatment. The results suggest that vitamin A plays an inbitory role in the activation and fibrogenesis ofIto cells after CBDL.
Rats ; Animals

No abstract available.
Heart* ; Hyperbilirubinemia* ; Thoracic Surgery*

No abstract available.
Dermatomyositis* ; Lymphoma, Follicular*

No abstract available.
Cellulitis* ; Klebsiella pneumoniae* ; Osteomyelitis*

No abstract available.
Neck* ; Nevus* ; Sebaceous Glands*

No abstract available.
Hand* ; Neutrophils* ; Skin Diseases* ; Sweet Syndrome

No abstract available.
Acanthoma* ; Nose*

Since opening of the Yeungnam University Hospital in March 1983 till the end of 1986, total 156 cases of brain atrophy and encephalopathy (control) diagnosed at the neurology department were investigated, adopting C.T. criteria of brain atrophy. Among the 156 only 77 cases had available C.T. films. Of the 77,35 cases were normal (control) and 42 had brain atrophy. The following results are obtained: 1. A new C.T. criteria of brain atrophy and its degree were devised. (Table 8.9) 2. As the age increased, number of brain atrophy cases increased. 3. Degree of EEG abnormalities were not parallel with the degree of brain atrophy. 4. The most frequent EEG abnormalities with or without brain atrophy were moderate abnormalities. 5. The EEG abnormalities were improved with treatment in most of the cases. 6. The group with suspected organic brain lesions had 69% cases of brain atrophy, whereas the group with only headache or dizzines had 57% of no atrophy. 7. There exists a clinical entity of "Cryptogenic Brain Atrophy". (Park) 8. Recent literatures of Brain Atrophy were reviewed.
Atrophy* ; Brain* ; Electroencephalography ; Headache ; Neurology

Hormone replacement therapy combined with progestogens induces changes in effect of estrogen on serum lipid levels and it has been known that the changes depend on a type and dosage of progestogen. It is also known that progestational agent induces positive ch-ange in bone mineral density. To study the effects of progestogen on lipoprotein and bone metabolism, we administ- ered conjugated equine estrogen 0.625 mg alone to 50 postmenopausal women, in combinat- ion with medroxy- progesterone acetate 5 mg to 40 postmenopausal women. The data demonstrated a beneficial effect in lipoprotein profiles in both groups. Total cholesterol in two groups decreased from the baseline values, LDL-cholesterol decreased significantly by 4.8 % in group I and 16.2 % in group II(p < 0.05), HDL-cholesterol increa- sed significantly by 11.3 % in group I and 14.7 % in group II(p < 0.05), triglyceride incre- ased slightly in both groups. Bone mineral density of femur was maintained and BMD of vertebrae increased by 1.1 % in group I and 2.0 % in group II, but it is not statistically significant. The differences of changes between two groups were not statistically significa- nt. Our results suggest that medroxyprogesterone acetate have no adverse effect on HDL -cholesterol and have no additive effect on bone mineral density in hormone replacement therapy.
Bone Density* ; Cholesterol ; Estrogens* ; Female ; Femur ; Hormone Replacement Therapy ; Humans ; Lipoproteins ; Medroxyprogesterone Acetate ; Metabolism ; Progesterone ; Progestins ; Spine ; Triglycerides